Temporal trends and risk factors for parathyroidectomy in the Swedish dialysis and transplant population – a nationwide, population-based study 1991 – 2009

BMC Nephrology

Martin Almquist¹  Karl Göran Prütz⁵  Rebecca Rylance³  Philippe Wagner³  Eva Reihnér⁴  Bengt Rippe²  Gunnar Sterner⁶  Naomi Clyne²  Shahriar Akaberi² 

[1]Section of Endocrine and Sarcoma Surgery, Department of Surgery, Skane University Hospital, Lund, Sweden

[2]Department of Nephrology, Clinical Sciences Lund, Lund University, Alwallhuset, Barngatan 2A, Lund 221 85, Sweden

[3]National Registry Centre, Skane University Hospital, Lund, Sweden

[4]Scandinavian Quality Register for Thyroid Parathyroid and Adrenal Surgery, Helsingborg, Sweden

[5]Swedish Renal Registry, Ryhov Hospital, Jönköping, Sweden

[6]Department of Nephrology, Clinical Sciences Malmö, Lund University, Lund, Sweden

关键词: Parathyroidectomy;    Secondary hyperparathyroidism;    Renal transplantation;    Dialysis;    End stage renal disease;   

Others  :  1082687
DOI  :  10.1186/1471-2369-15-75

 received in 2014-01-29, accepted in 2014-05-01,  发布年份 2014

【 摘 要 】

Background

Many patients on renal replacement therapy (RRT) require parathyroidectomy (PTX). Trends and current rates of PTX on a national level are not known. Furthermore, it is not completely clear which factors influence rates of PTX. Thus, our aim was to investigate the incidence, regional distribution and factors associated with PTX as well as possible temporal changes, in the Swedish RRT population.

Methods

From the Swedish Renal Registry we extracted data on 20 015 patients on RRT between 1991 and 2009. In these, 679 incident PTX (3.4%) were identified by linkage with the National Inpatient Registry, and the Scandinavian Quality Registry for Thyroid Parathyroid and Adrenal Surgery. Poisson models were used to estimate rates per calendar year, adjusted for risk factors such as gender, age, time with renal transplant, and underlying cause of renal disease.

Results

The PTX rate was 8.8/1 000 person-years. There was a significant increase 2001–2004 after which the rate fell, as compared with year 2000. Female gender, non-diabetic cause of renal disease and age between 40–55 were all associated with an increased frequency of PTX.

Conclusion

The rise in PTX rates after year 2000 might reflect increasing awareness of the potential benefits of PTX. The introduction of calcimimetics and paricalcitol might explain the decreased rate after 2005.

【 授权许可】

   
2014 Akaberi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, Weiss NS, Stehman-Breen CO: Parathyroidectomy rates among United States dialysis patients: 1990–1999. Kidney Int 2004, 65(1):282-288.
• [2]Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ: The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005, 16(1):210-218.
• [3]Li S, Chen YW, Peng Y, Foley RN, St Peter WL: Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis 2007, 57(4):602-611.
• [4]Slinin Y, Foley RN, Collins AJ: Clinical epidemiology of parathyroidectomy in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Hemodial Int 2007, 11(1):62-71.
• [5]Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F: Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 2001, 12(6):1242-1248.
• [6]Swedish Renal Registry http://www.medscinet.net/snr webcite
• [7]Swedish National Board of Health and Welfare http://www.socialstyrelsen.se/english webcite
• [8]Scandinavian Quality register for Thyroid Parathyroid and Adrenal Surgery http://www.thyroid-parathyroidsurgerty.com/ webcite
• [9]Schon S, Ekberg H, Wikstrom B, Odén A, Ahlmén J: Renal replacement therapy in Sweden. Scand J Urol Nephro 2004, 38(4):332-339.
• [10]Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO: External review and validation of the Swedish national inpatient register. BMC Public Health 2011, 11:450. BioMed Central Full Text
• [11]Bonarek H, Merville P, Bonarek M, Moreau K, Morel D, Aparicio M, Potaux L: Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999, 56(2):642-649.
• [12]Tokuyama K, Iseki K, Yoshi S, Yoshihara K, Nishime K, Uehara H, Tozawa M, Wake T, Arakaki M, Fukiyama K: An epidemiologic analysis of parathyroidectomy in chronic dialysis patients. The Okinawa Dialysis Study Group. Nihon Jinzo Gakkai Shi 1996, 38(7):309-313.
• [13]Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001, 12(10):2131-2138.
• [14]Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31(4):607-617.
• [15]Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008, 52(3):519-530.
• [16]Goodman WG, Goldin J, Kuizon BD, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342(20):1478-1483.
• [17]National Kidney foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42(3):S1-201.